{"id":"W4321375958","doi":"10.3389/fimmu.2023.1086102","title":"VISTA expression and patient selection for immune-based anticancer therapy","year":2023,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Heart, Lung, and Blood Institute; EMD Serono; Genentech; Astellas Pharma; Eisai; EQRx; Y-mAbs Therapeutics; Daiichi Sankyo Europe; Calithera Biosciences; Pfizer; Incyte; G1 Therapeutics; Jounce Therapeutics; Syndax Pharmaceuticals; BeiGene; Mirati Therapeutics; GlaxoSmithKline; Tizona Therapeutics; National Institutes of Health; Regeneron Pharmaceuticals; National Center for Advancing Translational Sciences; Helsinn; Loxo Oncology; Ribon Therapeutics; Array BioPharma; Exelixis; Sanofi; OncoMed Pharmaceutical; Relay Therapeutics; Amgen; AstraZeneca; Eli Lilly and Company","keywords":"Immunotherapy; Tumor microenvironment; Cytotoxic T cell; Cancer research; Immune system; T cell; Antigen; Myeloid-derived Suppressor Cell; Immune checkpoint; Myeloid; Cancer immunotherapy; Biology; Immunology; Suppressor; Cancer; In vitro; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005490158,0.00042938,0.001025371,0.00106558,0.0001017814,0.0005983924,0.0004729935,0.0006944838,0.001309485],"category_scores_gemma":[0.0007278444,0.0001329973,0.000339606,0.0008280456,0.0002579636,0.0005375248,0.0003588084,0.001139693,0.0006478711],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000510346,"about_ca_system_score_gemma":0.0005545098,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004215504,"about_ca_topic_score_gemma":0.0007728456,"domain_scores_codex":[0.9998191,0.00004942213,0.00002723346,0.00003251386,0.00005713521,0.00001470158],"domain_scores_gemma":[0.9997677,0.0001330309,0.0000365694,0.000004209102,0.00004628955,0.00001224116],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001055222,0.00004355441,0.000375143,0.009966629,0.0001230751,0.0001285018,0.00002618005,0.0003265507,0.001431524,0.002228853,0.01127016,0.9739743],"study_design_scores_gemma":[0.0000589369,0.0002701739,0.003555813,0.008565588,0.0004249447,0.002831162,0.00006228873,0.0002960292,0.001647273,0.002741336,0.9795135,0.00003316488],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001709784,0.999064,0.00009450164,0.0001792083,0.000071456,0.000002757559,0.00001017035,0.000003506554,0.0004034283],"genre_scores_gemma":[0.002126235,0.9969799,0.000205651,0.0002295052,0.0001113159,0.000008820666,0.00003321762,0.000001257965,0.0003040047],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001309485,"threshold_uncertainty_score":0.004380643,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03256756051722987,"score_gpt":0.3256557732942972,"score_spread":0.2930882127770673,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}